Global Hepatitis B Virus (HBV) Vaccine Market (by End User, Composition, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)

Global Hepatitis B Virus (HBV) Vaccine Market (by End User, Composition, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)

Market Insight:

The hepatitis B virus (HBV) is a virus that infects the liver. It is spread through contact with an infected person's blood or bodily fluids. Sexual contact, sharing needles or other drug injection equipment, or being exposed to blood or body fluids in a healthcare setting can all lead to this. During childbirth, an infected mother can pass the virus to her baby. Hepatitis B is a serious infection that can lead to long-term health issues such as liver damage, cirrhosis, and liver cancer.

The hepatitis B vaccine is an effective method of preventing hepatitis B virus infection. Vaccination is a key intervention in the World Health Organization's (WHO) efforts to eradicate hepatitis B virus (HBV) by 2030. Since the first hepatitis B vaccine was approved in 1981, there has been significant progress in hepatitis B vaccines. Vaccine recommendations have also evolved over several decades, culminating in the recommendation for universal hepatitis B immunisation for all people under the age of 60. The global hepatitis B virus (HBV) vaccine market is expected to be worth US$2.47 billion in 2023, witnessing growth at a CAGR of 5.33%, during the projected period.

Segment Covered:

• By End User: In terms of end user, the report offers insights of the global hepatitis B virus (HBV) vaccine market into two segments: Adult and Pediatric. Adult HBV vaccine segment is further divided into two segment on the basis of composition: mono vaccine and combination vaccine. The combination vaccines segment is anticipated to grow at the fastest rate during the forecasted period, due to its properties of protection against multiple causal agents. The combination vaccine also reduces the cost of packaging for individual vaccines, which would contribute to the segment market growth. For example, the Twinrix combination vaccine can protect against both hepatitis B and hepatitis A.

Geographic Coverage:

According to this report, the global hepatitis B virus (HBV) vaccine market is divided into five regions: The US, China, European Union, Japan, and ROW. The US occupied the dominant share in the global market. The hepatitis B vaccine market in the US is a significant market, with a high demand for the vaccine due to the ongoing threat of hepatitis B virus (HBV) infection. The market is expected to continue to grow in the coming years, driven by factors such as the increasing prevalence of HBV, government initiatives and policies to promote vaccination, technological advances in vaccine production, and increasing healthcare expenditure.

European Union and the UK market is expected to expand significantly during the forecast period. Various reasons such as improved healthcare infrastructure, an active government drive to track HBV, and a well-established reimbursement system for hospitals, are expected to drive the growth of the market in European Union. In addition, Public Health England is constantly updating the country's HBV infection burden, relating it to economic burden, statistical modelling, and estimating vaccination cost-effectiveness. These types of studies are also expected to propel the growth of the market in EU. Furthermore, the market's growth is projected to be influenced by ongoing technological advancements, greater accessibility, and rising disposable income. Companies would adjust to changing market conditions and tailor their business plans and practices to aid in the growth of the HBV vaccination in the region.

Top Impacting Factors:

Growth Drivers

• Increasing Geriatric Population
• Increasing Healthcare Expenditure
• Growing Instances of HBV Among Infants
• Increase in Liver Cancer and Cirrhosis Deaths due to HBV

Challenges

• High Cost of Vaccine Development
• Inequitable Access to Vaccines

Trends

• Use of AI in Vaccine and Drug Design
• Technological Advancements in Vaccine Administration
• Favorable Government Initiatives and Policies
• Driver: Growing Instances of HBV Among Infants

The growing instances of hepatitis B virus (HBV) infection among infants can increase the demand for HBV vaccine. HBV infection is transmitted through contact with infected blood or bodily fluids, and can be passed from an infected mother to her newborn during childbirth. This is called perinatal transmission. Perinatal transmission of HBV is a significant public health problem, as it can lead to chronic HBV infection in infants. Chronic HBV infection can cause serious health complications, including liver cirrhosis and liver cancer. To prevent perinatal transmission of HBV, the World Health Organization (WHO) recommends that all pregnant women be tested for HBV infection and that infants of HBV-positive mothers receive the HBV vaccine as soon as possible after birth. The growing instances of HBV infection among infants can increase the demand for HBV vaccine as more parents seek to protect their children against the virus, boosting the HBV vaccine market.

• Challenge: Inequitable Access to Vaccines

Inequitable access to vaccines have been observed and is a critical issue in the market, particularly in impoverished areas where awareness programs and initiatives have either failed to permeate or have not penetrated sufficiently. In some circumstances, vaccinations may be difficult to obtain due to a lack of adequate storage facilities and government backing, such as in distant areas. Access to immunization has also been limited due to other constraints such as low literacy rates, a lack of health knowledge, and financial limitations. Furthermore, the development and distribution of HBV vaccines and antibodies in deprived areas is unequal, which is considered as a stumbling block to the market's growth.

• Trend: Use of AI in Vaccine and Drug Design

Biochemistry, structural biology, immunological principles, microbiology, and genomics have all seen significant advances in recent years. In addition, the fields of data science, informatics, and artificial intelligence have seen considerable expansion in order to handle this massive data influx. The field of bioinformatics, which tries to use computer techniques to a better understanding of biological sciences, sits at the crossroads of wet lab and data science. Bioinformatics has revolutionized immunology research, as it has many other fields of biology, resulting in the discipline of immunoinformatics. Many new databases and computational tools have been developed in this sector to advance immunology research, with many of them relying on artificial intelligence and machine learning to anticipate complicated immune system activities, such as B cell and T cell epitope prediction. The use of AI in vaccine and medication design and development is predicted to reduce vaccine development time while also increasing vaccine efficacy, propelling the growth of HBV vaccine market in the coming years.

The COVID-19 Analysis:

The COVID-19 pandemic has had a profound impact on the hepatitis B virus (HBV) vaccine market. One of the main impacts of COVID-19 on HBV vaccines has been a disruption in the production and supply chain for vaccines. The pandemic has caused disruptions in the supply of raw materials and other inputs needed for vaccine production, as well as in the transportation and distribution of vaccines. This has led to shortages of HBV vaccines and other vaccines in some areas. In addition, the focus on responding to the COVID-19 pandemic has led to delays or reductions in funding for other vaccination programs, including HBV vaccination programs. This may have had an impact on vaccination rates for HBV and other diseases.

Despite the short-term challenges posed by the pandemic, the post COVID outlook for the hepatitis B virus (HBV) vaccine market looks positive. The COVAX Facility, which is led by the World Health Organization (WHO) and aims to provide equitable access to COVID-19 vaccines, has also been working to ensure access to other essential vaccines, including the hepatitis B vaccine. The COVAX Facility has secured more than 2 billion doses of the hepatitis B vaccine and has delivered them to countries around the world. These efforts would drive the production of HBV vaccines during the post COVID period.

Analysis of Key Players:

Global hepatitis B virus (HBV) vaccine market is moderately concentrated, with increasing acquisitions, collaboration, and product launches. Past decades have seen rise in studies on characteristics of anti-HBs antibodies, pertaining to neonates, infants, adults, and immune suppressed patients. Top players have been trying to incorporate the results of multicenter studies in a bid to improve response to HBV vaccination, with a direct focus on HBV mutants. The key players in the global hepatitis B virus (HBV) vaccine market are:

• Merck & Co., Inc.
• GlaxoSmithKline
• Sanofi
• VBI Vaccines Inc.
• Shenzhen Kangtai Biological Products Co., Ltd.
• Dynavax Technologies Corporation
• Meiji Group (KM Biologics)
• LG Chem Ltd.
• Cyrus Poonawalla Group (Serum Institute of India Pvt.)
• Indian Immunologicals Limited

Due to the concentration of key players in developed regions, regional partnerships and distribution agreements have become major strategic initiatives for a number of key players. Numerous new entrants and established players also eye potential avenues in chronic HBV infected patients and intend to conduct more research on therapeutic vaccination. In March 2022, VBI Vaccines Inc. received the US Food and Drug Administration approval for the only 3-antigen HBV vaccine for adults in the US, PreHevbrio for hepatitis B.